CONTEXT: c-Met is important in the pathogenesis, invasion, and spread of several forms of lung cancer, and multiple c-Met inhibitors are undergoing clinical trials. PAX5 has been shown to upregulate c-Met in small cell lung carcinoma (SCLC), and coinhibiting PAX5 and c-Met had a synergic effect in killing tumor cells. Paxillin is a downstream target of activated c-Met, and its activation leads to enhanced cell motility and tumor spread. The expression patterns of these functionally related proteins have not, to our knowledge, been systemically studied in neuroendocrine tumors of the lung. OBJECTIVE: To investigate the expression patterns of PAX5, paxillin, c-Met, and phosphorylated c-Met in 4 categories of pulmonary neuroendocrine tumors. DESIGN: Tissue microarrays of 38 typical carcinoids, 6 atypical carcinoids, 34 SCLCs, and 11 large cell neuroendocrine carcinomas were studied with immunohistochemistry. RESULTS: Most of the 4 tumor types expressed c-Met, phosphorylated c-Met, and paxillin. PAX5 was frequently expressed in atypical carcinoids, SCLCs, and large cell neuroendocrine carcinomas but tended to be negative in typical carcinoids. Coexpression of PAX5 with c-Met or phosphorylated c-Met was present in most of the atypical carcinoids, SCLCs, and large cell neuroendocrine carcinomas. Significant correlation between PAX5 and paxillin was detected in SCLCs and large cell neuroendocrine carcinomas but not in carcinoid tumors. CONCLUSIONS: The frequent coexpression of PAX5 with c-Met or phosphorylated c-Met in intermediate-grade and high-grade neuroendocrine tumors supports the therapeutic strategy of coinhibiting these proteins. The discrepancy between high-grade and low-grade neuroendocrine tumors in PAX5/paxillin expression correlation may be due to the different underlying molecular genetics of these tumors.
CONTEXT: c-Met is important in the pathogenesis, invasion, and spread of several forms of lung cancer, and multiple c-Met inhibitors are undergoing clinical trials. PAX5 has been shown to upregulate c-Met in small cell lung carcinoma (SCLC), and coinhibiting PAX5 and c-Met had a synergic effect in killing tumor cells. Paxillin is a downstream target of activated c-Met, and its activation leads to enhanced cell motility and tumor spread. The expression patterns of these functionally related proteins have not, to our knowledge, been systemically studied in neuroendocrine tumors of the lung. OBJECTIVE: To investigate the expression patterns of PAX5, paxillin, c-Met, and phosphorylated c-Met in 4 categories of pulmonary neuroendocrine tumors. DESIGN: Tissue microarrays of 38 typical carcinoids, 6 atypical carcinoids, 34 SCLCs, and 11 large cell neuroendocrine carcinomas were studied with immunohistochemistry. RESULTS: Most of the 4 tumor types expressed c-Met, phosphorylated c-Met, and paxillin. PAX5 was frequently expressed in atypical carcinoids, SCLCs, and large cell neuroendocrine carcinomas but tended to be negative in typical carcinoids. Coexpression of PAX5 with c-Met or phosphorylated c-Met was present in most of the atypical carcinoids, SCLCs, and large cell neuroendocrine carcinomas. Significant correlation between PAX5 and paxillin was detected in SCLCs and large cell neuroendocrine carcinomas but not in carcinoid tumors. CONCLUSIONS: The frequent coexpression of PAX5 with c-Met or phosphorylated c-Met in intermediate-grade and high-grade neuroendocrine tumors supports the therapeutic strategy of coinhibiting these proteins. The discrepancy between high-grade and low-grade neuroendocrine tumors in PAX5/paxillin expression correlation may be due to the different underlying molecular genetics of these tumors.
Authors: W D Travis; R I Linnoila; M G Tsokos; C L Hitchcock; G B Cutler; L Nieman; G Chrousos; H Pass; J Doppman Journal: Am J Surg Pathol Date: 1991-06 Impact factor: 6.394
Authors: Patrick C Ma; Takashi Kijima; Gautam Maulik; Edward A Fox; Martin Sattler; James D Griffin; Bruce E Johnson; Ravi Salgia Journal: Cancer Res Date: 2003-10-01 Impact factor: 12.701
Authors: Ramasamy Jagadeeswaran; Hanna Surawska; Soundararajan Krishnaswamy; Varalakshmi Janamanchi; A Craig Mackinnon; Tanguy Y Seiwert; Sivakumar Loganathan; Rajani Kanteti; Trevor Reichman; Vidya Nallasura; Stuart Schwartz; Leonardo Faoro; Yi-Ching Wang; Luc Girard; Maria S Tretiakova; Salman Ahmed; Osvaldo Zumba; Lioubov Soulii; Vytas P Bindokas; Livia L Szeto; Gavin J Gordon; Raphael Bueno; David Sugarbaker; Mark W Lingen; Martin Sattler; Thomas Krausz; Wickii Vigneswaran; Viswanathan Natarajan; John Minna; Everett E Vokes; Mark K Ferguson; Aliya N Husain; Ravi Salgia Journal: Cancer Res Date: 2008-01-01 Impact factor: 12.701
Authors: Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne Journal: Science Date: 2007-04-26 Impact factor: 47.728
Authors: Jin-Ping Lai; Richard B Mertens; James Mirocha; Jamie Koo; Mariza Venturina; Fai Chung; Allen B Mendez; Melissa Kahn; Deepti Dhall Journal: Endocr Pathol Date: 2015-03 Impact factor: 3.943
Authors: Elke Tatjana Aristizabal Prada; Gerald Spöttl; Julian Maurer; Michael Lauseker; Eva Jolanthe Koziolek; Jörg Schrader; Ashley Grossman; Karel Pacak; Felix Beuschlein; Christoph Joseph Auernhammer; Svenja Nölting Journal: Endocr Relat Cancer Date: 2018-06-12 Impact factor: 5.678
Authors: Varune Rohan Ramnarine; Mohammed Alshalalfa; Fan Mo; Noushin Nabavi; Nicholas Erho; Mandeep Takhar; Robert Shukin; Sonal Brahmbhatt; Alexander Gawronski; Maxim Kobelev; Mannan Nouri; Dong Lin; Harrison Tsai; Tamara L Lotan; R Jefferey Karnes; Mark A Rubin; Amina Zoubeidi; Martin E Gleave; Cenk Sahinalp; Alexander W Wyatt; Stanislav V Volik; Himisha Beltran; Elai Davicioni; Yuzhuo Wang; Colin C Collins Journal: Gigascience Date: 2018-06-01 Impact factor: 6.524